Other
Hallux Valgus
13
Pipeline Programs↗
2
Active Trials↗
9
Companies Involved↗
Hallux valgus is an emerging landscape with 13 programs across 9 companies. The most active players are Beijing Tide Pharmaceutical Co., Ltd, Merck & Co., Novartis. 8 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 21
Analysis
Trial Status
10
clinical trials
Completed5 · 50%
Unknown status2 · 20%
Not yet recruiting1 · 10%
Withdrawn1 · 10%
Recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
Effect of Botulinum Toxin to Hallux Valgus in Addition to Total Contact Insole
Completed·—·Phase 4·NCT01501500·25 enrolled
A Phase 1 Study of Intraoperative Administration of CA-008 for the Correction of Hallux Valgus Deformity
Completed·—·Phase 1·NCT03307837·40 enrolled
Ultrasound Guided Single Shot Block of Posterior Tibial Nerve for Postoperative Pain Relief After Hallux Valgus Surgery
Unknown status·—·Phase 4·NCT02282956·60 enrolled
Preemptive Analgesic Effects of Popliteal Sciatic Nerve Block in Patients With Bilateral Hallux Valgus Surgery
Unknown status·—·N/A·NCT03414593·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)